Tokyo-based startup SORA Technology has secured approximately $4.8m (JPY 670m) in a late seed funding round, as the company seeks to expand its drone and AI-powered health infrastructure across Africa.
The round saw participation from a number of Japanese institutional investors including Nissay Capital’s Sustainability Challenge Fund, SMBC Venture Capital, DRONE FUND, Central Japan Seed Fund, and Rheos Capital Works. The figure includes a portion of debt financing and marks the company’s cumulative capital raised to date.
Founded by Yosuke Kaneko, SORA Technology is developing drone and AI systems aimed at tackling infectious diseases and climate-related health risks. The company currently operates in six African countries — Ghana, Sierra Leone, Benin, the Democratic Republic of Congo, Senegal, and Kenya — where it works in partnership with governments, research institutions, and global health organisations.
The startup’s flagship programme, SORA Malaria Control, deploys drones for vector control, such as spraying targeted areas to reduce mosquito populations, alongside AI-driven disease forecasting tools that aim to predict outbreaks and inform public health responses.
The funding, SORA said, will support several fronts: advancing its AI algorithms for disease prediction, scaling field operations, enhancing its drone fleet, and reinforcing collaborations with African governments and international agencies. The company is also planning to grow its team in Africa and Japan to support the expanded scope of work.
“The support we’ve received affirms that our vision — to eliminate preventable deaths from infectious diseases — resonates across sectors,” said Kaneko in a statement. “This funding will allow us to accelerate product development, scale local operations, and strengthen our foundation as we expand into more communities.”
SORA’s work has drawn increasing international attention as global health, climate resilience, and technology converge on the development agenda. In 2023, the company was selected to join the Triple I (Impact Investment Initiative) for Global Health, a programme promoted at the G7 Hiroshima Summit to catalyse private capital for health-focused enterprises in low- and middle-income countries.
The participation of sustainability-focused investors, such as Nissay Capital, signals broader investor interest in the role of frontier technologies in solving public health challenges, especially in regions with limited medical infrastructure.
While much of the attention on climate-tech startups remains focused on mitigation — such as renewable energy or emissions tracking — SORA’s model combines climate adaptation and health infrastructure in settings vulnerable to the double burden of disease and environmental shocks.
Founded in Japan, SORA operates with a dual footprint in Asia and Africa. In addition to malaria, the company is exploring applications of its platform for other diseases and emergencies — including disaster response and agricultural resilience — with ambitions to create what it calls “life-saving social infrastructure” tailored to local realities.
As international donors and governments increasingly seek scalable, technology-enabled solutions to long-standing development challenges, companies like SORA are positioning themselves as intermediaries between innovation and impact.
Whether these early pilots can translate into sustainable public-private partnerships remains to be seen. But with new capital and institutional backing, SORA now enters a critical phase of proving its model at scale — on a continent where the stakes remain high, and the need for innovation is urgent.